Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response

通过 DNA 损伤反应的治疗靶向来提高放化疗敏感性

基本信息

项目摘要

ABSTRACT There is an urgent need to improve the efficacy of chemoradiation therapy for patients with locally advanced pancreatic cancer (LAPC). Since unrepaired DNA double-strand breaks (DSB) are responsible for the majority of cell death in response to chemoradiation, targeting cellular DNA damage response (DDR) pathways is a promising approach to enhance the efficacy of chemoradiation therapy by preventing efficient repair of DNA damage, leading to loss of tumor cell viability. Since defects in the DDR such as P53 mutation occur in up to 70% of pancreatic ductal adenocarcinomas (PDAC), targeted inhibition of the DDR provides an opportunity to selectively enhance sensitivity to chemoradiation in tumor but not normal cells. The overall goal of our proposed study is to identify agents from the CTEP collection that modulate the cellular response to DNA damage and best sensitize tumor cells to standard of care chemoradiation therapy. To achieve this goal, we will in Aim 1 conduct an unbiased high throughput screen (HTS) in a panel of PDAC cell lines using a panel of agents from the CTEP collection that modulate the cellular DDR, including drugs that target ATR, DNAPK, PARP, and WEE1 (Aim 1A). An initial cell viability screen at various concentrations of single agents alone or in combination with chemoradiation will be conducted. In addition to concentration, optimal sequencing of targeted agents with chemoradiation will be investigated. A live cell assay for the DDR as well as apoptotic cell death will be utilized as orthogonal screens to assist in hit prioritization and validation. In Aim 1B, a group of agents selected by defined criteria will be further evaluated by conducting a “gold standard” clonogenic survival assay using a panel of PDAC cell lines. In Aim 1C we will conduct a normal cell counter screen using the above agents against normal cells to identify those which cause toxicity in combination with chemoradiation. The efficacy of these prioritized agents will be validated in Aim 1D using a panel of patient- derived xenograft (PDX) sphere explant cultures. Two agents with the optimal enhancement ratio (1B and 1D), and safety (1C) at the optimal concentration and schedule (1A and 1B) will be studied in Aim 2. We will compare the therapeutic efficacy of the nominated agents in combination with chemoradiation using both PDX and immune competent syngeneic mouse models of PDAC (Aim 2A). Normal tissue injury caused by these two agents (Aim 2B) will be evaluated, which together with tumor efficacy will lead to the choice of the agent to pursue in clinical trials. Aim 3 will delineate the mechanistic basis for the chemoradiation potentiating activity of the superior agent (Aim 3A) with the goal of selecting pharmacodynamic and imaging biomarkers (Aims 3B and 3C), using in vivo studies in mouse models, for the future clinical trial. Completion of these aims will provide the required preclinical data regarding efficacy, safety, and biomarkers of response (mechanistic- and imaging- based) for the rationale design of a future clinical trial for patients with LAPC.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THEODORE S LAWRENCE其他文献

THEODORE S LAWRENCE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THEODORE S LAWRENCE', 18)}}的其他基金

Molecularly Targeted Radiosensitization of Locally Advanced Cancers
局部晚期癌症的分子靶向放射增敏
  • 批准号:
    10554470
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10554471
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors
靶向基质对 PDAC 肿瘤 BCKA 成瘾的影响
  • 批准号:
    10453984
  • 财政年份:
    2022
  • 资助金额:
    $ 58.21万
  • 项目类别:
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors
靶向基质对 PDAC 肿瘤 BCKA 成瘾的影响
  • 批准号:
    10581670
  • 财政年份:
    2022
  • 资助金额:
    $ 58.21万
  • 项目类别:
Development of a first-in-class mEGFR dimerization inhibitor
开发一流的 mEGFR 二聚化抑制剂
  • 批准号:
    10591476
  • 财政年份:
    2020
  • 资助金额:
    $ 58.21万
  • 项目类别:
Development of a first-in-class mEGFR dimerization inhibitor
开发一流的 mEGFR 二聚化抑制剂
  • 批准号:
    10435117
  • 财政年份:
    2020
  • 资助金额:
    $ 58.21万
  • 项目类别:
Development of a first-in-class mEGFR dimerization inhibitor
开发一流的 mEGFR 二聚化抑制剂
  • 批准号:
    10369006
  • 财政年份:
    2020
  • 资助金额:
    $ 58.21万
  • 项目类别:
Development of a first-in-class mEGFR dimerization inhibitor
开发一流的 mEGFR 二聚化抑制剂
  • 批准号:
    10778673
  • 财政年份:
    2020
  • 资助金额:
    $ 58.21万
  • 项目类别:
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
基于机制的 Chk1 抑制剂在胰腺癌中的应用
  • 批准号:
    8242063
  • 财政年份:
    2010
  • 资助金额:
    $ 58.21万
  • 项目类别:
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
基于机制的 Chk1 抑制剂在胰腺癌中的应用
  • 批准号:
    7891047
  • 财政年份:
    2010
  • 资助金额:
    $ 58.21万
  • 项目类别:

相似海外基金

Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
  • 批准号:
    520728-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
    University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    10368760
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    10669539
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    9570142
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    9915803
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
  • 批准号:
    10259999
  • 财政年份:
    2017
  • 资助金额:
    $ 58.21万
  • 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
  • 批准号:
    21580130
  • 财政年份:
    2009
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
  • 批准号:
    300985-2004
  • 财政年份:
    2005
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
  • 批准号:
    300985-2004
  • 财政年份:
    2004
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Postdoctoral Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了